D.B. Root & Company LLC purchased a new position in shares of Merck KGaA (OTCMKTS:MKGAF – Free Report) in the 2nd quarter, Holdings Channel.com reports. The firm purchased 3,564 shares of the company’s stock, valued at approximately $458,000.
Other hedge funds have also recently modified their holdings of the company. Barrow Hanley Mewhinney & Strauss LLC purchased a new position in Merck KGaA in the 2nd quarter valued at $942,087,000. Bank of Nova Scotia purchased a new position in Merck KGaA during the 2nd quarter worth $281,696,000. Danske Bank A S acquired a new stake in shares of Merck KGaA in the 2nd quarter worth $276,535,000. Korea Investment CORP acquired a new stake in shares of Merck KGaA in the 2nd quarter worth $239,191,000. Finally, Cibc World Market Inc. purchased a new stake in shares of Merck KGaA in the second quarter valued at about $186,005,000. 0.10% of the stock is owned by institutional investors and hedge funds.
Merck KGaA Stock Performance
Shares of Merck KGaA stock opened at $163.21 on Monday. The firm has a market cap of $21.09 billion, a price-to-earnings ratio of 24.92 and a beta of 0.96. Merck KGaA has a 52-week low of $116.68 and a 52-week high of $175.56. The company’s 50-day simple moving average is $162.62 and its 200-day simple moving average is $148.44. The company has a quick ratio of 0.84, a current ratio of 1.31 and a debt-to-equity ratio of 0.27.
Merck KGaA Company Profile
Merck KGaA, headquartered in Darmstadt, Germany, is a long-established multinational chemical and pharmaceutical company with roots dating back to 1668. Operating under the brand Merck Group (and using distinct consumer-facing names in certain regions to avoid confusion with other companies of similar name), the company is privately controlled by the Merck family and organizes its activities across multiple business units that serve customers in Europe, the Americas, Asia-Pacific and beyond.
The company’s operations are organized mainly into three businesses.
Further Reading
- Five stocks we like better than Merck KGaA
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Want to see what other hedge funds are holding MKGAF? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck KGaA (OTCMKTS:MKGAF – Free Report).
Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.
